Quintiles backs away from possible ClinPhone bid; Introgen files first gene therapy for FDA approval;

> After flirting with the idea of making a competing offer for ClinPhone, Quintiles Transnational has backed away from the table, giving Parexel a clear path to completing its planned acquisition. Report

> After 14 years of research, Introgen Therapeutics is asking the FDA to give its BLA for a gene-based therapy for head and neck cancer--Advexin--a priority review. Report

> Shares of SuperGen took a dive after the company revealed that Dacogen failed a late-stage trial for the bone marrow disease MDS. Report

> CoLucid Pharmaceuticals says it has rounded up $25 million in Series B financing. VC report

> Sangamo BioSciences has reported new work in Nature Biotechnology demonstrating the effectiveness of its zinc finger DNA-binding proteins in immunizing cells in the immune system against HIV. Sangamo report

> The drumbeat of criticism over the impact of flat-line budgets at the NIH on the U.S. research community continues to build. In a recent article for the Star-Ledger, scientists report that original grant funding for projects dropped from 30 percent in 1999 to 12 percent today. Report

> A professor at the University of Texas in Austin has created a virtual supercomputer to study metastasis. Report

> Looking to raise its profile with U.S. drug developers, Xceleron is set to open its new, $7.5 million lab in Germantown, MD later today. Xceleron report

And Finally... About 20 years ago, Harvard researcher Donald Ingber accidentally stumbled on a mold that demonstrated a remarkable ability to prevent the growth of small blood vessels. Cancer report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.